Page 5 - Recent Corporate News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Trevena Reports Fourth Quarter 2023 Results and Provides Corporate Update

TRV045, novel S1P receptor modulator for chronic pain and epilepsy, advances toward important milestones in both non-clinical and clinical studies.

United statesCarrie bourdowBob yoderCompany contactEpilepsy therapy screening programCompany annual report on formNational institutes of healthLifesci advisorsExchange commissionTrevena incTrevena medical information contact centerRecent corporateSupported epilepsy therapy screening programFourth quarterNobel prizeNational institutes

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights

Fortress Biotech Reports 2023 Financial Results and Recent Corporate Highlights
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

South koreaRepublic ofHong kongUnited statesTony plohorosLindsaya rosenwaldJaclyn jaffeFred hutchinson cancer centerZydus lifesciences ltdFortress biotech incCompany contactAevitas therapeutics incSecurities exchangeMustang bio incCaelum biosciences incDrug administration

Inmune Bio Inc Announces Year End 2023 Results And Provides A Q4 Business Update

Inmune Bio Inc Announces Year End 2023 Results And Provides A Q4 Business Update
menafn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from menafn.com Daily Mail and Mail on Sunday newspapers.

United statesBritish columbiaUnited kingdomMark lowdellInmune bioDavid mossJason nelsonGlobe newswire inmune bio incDrug administrationInmune bio incSociety three pillars of valueCompany annual report on formExchange commissionCompany quarterly reports on formCompany current reports on formNasdaq company to host conference call

Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

Enrolled 12 participants in Phase 2 BESTOW trial evaluating tegoprubart for the prevention of kidney rejection

United statesStephen jasperEliezer katzDavid alexandrec grosAllan kirkJames robinsonDiabetes research foundationCure allianceEledon pharmaceuticalsGilmartin groupEledon pharmaceuticals incExchange commissionAmerican society of nephrology kidney weekUniversity of chicago transplantation instituteBerry company public relationsChief executive officer

Cellectar Biosciences Reports Financial Results for Year

Management to host a conference call today at 8:30 am ET.

United statesJames carusoCellectar biosciencesClaire lacagninaDevelopment expenseBliss bio healthCellectar biosciences incExchange commissionRecent corporateRosalind advisorsCash equivalentsAdministrative expenseEastern timePhospholipid drug conjugateEnded decemberNasdaq clrb